Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review

References

• Fleischmann M, Schnetzke U, Hochhaus A, et al. Management of acute myeloid leukemia: current treatment options and future perspectives. Cancers. 2021;13(22):5722.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642–4649.
   PubMed Web of Science ®Google Scholar
• Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the beat AML master trial. Nat Med. 2020;26(12):1852–1858.
   PubMed Web of Science ®Google Scholar
• Xu Q, He S, Yu L. Clinical benefits and safety of gemtuzumab ozogamicin in treating acute myeloid leukemia in various subgroups: an updated systematic review, meta-analysis, and network meta-analysis. Front Immunol. 2021;12:683595.
   PubMed Web of Science ®Google Scholar
• Lancet JE. Is the overall survival for older adults with AML finally improving? Best Pract Res Clin Haematol. 2018;31(4):387–390.
   PubMed Web of Science ®Google Scholar
• Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547–1573.
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–2934.
   PubMed Web of Science ®Google Scholar
• Estey E, Othus M, Lee SJ, et al. New drug approvals in acute myeloid leukemia: what’s the best end point? Leukemia. 2016;30(3):521–525.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019;134(12):935–945.
   PubMedGoogle Scholar
• Jeyakumar D, O'Brien S. Minimal residual disease in acute myeloid leukemia. JAMA Oncol. 2020;6(12):1899–1900.
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189–1199.
   PubMed Web of Science ®Google Scholar
• Short NJ, Zhou S, Fu C, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6(12):1890–1899.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Rosenblum D, Arceci RJ, et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007;109(5):1810–1816.
   PubMed Web of Science ®Google Scholar
• Medeiros BC. Interpretation of clinical endpoints in trials of acute myeloid leukemia. Leuk Res. 2018;68:32–39.
   PubMed Web of Science ®Google Scholar
• Mbanya Z, Chadda S. Time to second objective disease progression (PFS2): an emerging clinical trial endpoint with regulatory and reimbursement implications. Blood. 2014;124(21):6005–6005.
   Web of Science ®Google Scholar
• Walter RB, Appelbaum FR, Tallman MS, et al. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood. 2010;116(14):2420–2428.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics guidance for industry. Rockville, MD (USA): Food and Drug Administration; 2019, Available online at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics.
   Google Scholar
• Panageas KS, Ben-Porat L, Dickler MN, et al. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2007;99:428–432.
   PubMed Web of Science ®Google Scholar
• Othus M, Sekeres MA, Nand S, et al. Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia. 2019;33(2):371–378.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508–1516.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hunter AE, et al. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood. 2013;122(8):1384–1394.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464.
   PubMed Web of Science ®Google Scholar
• Voso MT, Ottone T, Lavorgna S, et al. MRD in AML: the role of new techniques. Front Oncol. 2019;9:655.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Cuneo A, Pane F, et al. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. Haematologica. 2008;93(7):1017–1024.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Bixby D, Perl A, et al. NCCN guidelines insights: acute myeloid leukemia, version 2.2021. J Natl Compr Canc Netw. 2021;19(1):16–27.
   PubMed Web of Science ®Google Scholar
• Falini B, Sciabolacci S, Falini L, et al. Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field. Leukemia. 2021;35:3113–3126.
   PubMed Web of Science ®Google Scholar
• Dillon R, Hills R, Freeman S, et al. Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood. 2020;135(9):680–688.
   PubMed Web of Science ®Google Scholar
• Kapp-Schwoerer S, Weber D, Corbacioglu A, et al. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood. 2020;136(26):3041–3050.
   PubMed Web of Science ®Google Scholar
• Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival (PERDAM). Available at: https://clinicaltrials.gov/ct2/show/study/NCT03549351
   Google Scholar
• Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33(11):1258–1264.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment. FDA; 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and
   Google Scholar
• Abbasi S, Diab O, Mohyuddin GR, et al. In-Hospital morbidity and mortality among acute myeloid leukemia patients admitted for hematopoietic stem cell transplants between 2002–2014. Blood. 2019;134:2147–2147.
   Web of Science ®Google Scholar
• Alibhai SM, Breunis H, Timilshina N, et al. Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age. J Geriatr Oncol. 2015;6(4):262–271.
   PubMed Web of Science ®Google Scholar
• Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology Perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32(12):1277–1280.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Batist G, Kantarjian HM, et al. The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases. Clin Cancer Res. 2015;21(20):4561–4568.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463–471.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731.
   PubMed Web of Science ®Google Scholar
• Wei AH, Strickland SA Jr., Hou JZ, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–1284.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379–389.
   PubMed Web of Science ®Google Scholar